BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION Financials Biosino Bio-Technology and Science Incorporation
Equities
8247
CNE100000288
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.94 HKD | 0.00% |
|
+34.29% | +17.50% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 209.7 | 250.9 | 204.6 | 200.4 | 162.3 | 105.2 |
| Enterprise Value (EV) 1 | 203.3 | 363 | 355.8 | 323.2 | 229.7 | 184.6 |
| P/E ratio | -102 x | -2.27 x | 75.3 x | -176 x | 20 x | -9.03 x |
| Yield | 6.9% | - | - | - | - | - |
| Capitalization / Revenue | 0.69 x | 0.63 x | 0.63 x | 0.58 x | 0.44 x | 0.36 x |
| EV / Revenue | 0.67 x | 0.91 x | 1.09 x | 0.93 x | 0.62 x | 0.64 x |
| EV / EBITDA | 8.61 x | 9.08 x | 37.7 x | 6.47 x | 5.61 x | -104 x |
| EV / FCF | 4.22 x | 4.9 x | -8.52 x | 15.7 x | 5.13 x | -16 x |
| FCF Yield | 23.7% | 20.4% | -11.7% | 6.37% | 19.5% | -6.26% |
| Price to Book | 0.69 x | 1.44 x | 1.15 x | 1.14 x | 0.79 x | 0.5 x |
| Nbr of stocks (in thousands) | 144,707 | 144,707 | 144,707 | 144,707 | 144,707 | 144,707 |
| Reference price 2 | 1.449 | 1.734 | 1.414 | 1.385 | 1.122 | 0.7271 |
| Announcement Date | 3/28/19 | 3/30/21 | 3/31/21 | 3/30/22 | 3/31/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 303.2 | 397.4 | 325.3 | 348.2 | 373.1 | 289.1 |
| EBITDA 1 | 23.6 | 40 | 9.448 | 49.93 | 40.92 | -1.783 |
| EBIT 1 | -0.763 | 14.43 | -11.8 | 25.38 | 19.74 | -18.84 |
| Operating Margin | -0.25% | 3.63% | -3.63% | 7.29% | 5.29% | -6.52% |
| Earnings before Tax (EBT) 1 | -14.55 | -114.8 | 2.155 | 6.407 | 18.52 | -17.61 |
| Net income 1 | -2.049 | -110.4 | 2.718 | -1.14 | 8.106 | -11.65 |
| Net margin | -0.68% | -27.78% | 0.84% | -0.33% | 2.17% | -4.03% |
| EPS 2 | -0.0142 | -0.7630 | 0.0188 | -0.007877 | 0.0560 | -0.0805 |
| Free Cash Flow 1 | 48.16 | 74.01 | -41.77 | 20.58 | 44.77 | -11.55 |
| FCF margin | 15.88% | 18.62% | -12.84% | 5.91% | 12% | -3.99% |
| FCF Conversion (EBITDA) | 204.09% | 185.03% | - | 41.21% | 109.43% | - |
| FCF Conversion (Net income) | - | - | - | - | 552.36% | - |
| Dividend per Share 2 | 0.1000 | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/30/21 | 3/31/21 | 3/30/22 | 3/31/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 112 | 151 | 123 | 67.4 | 79.4 |
| Net Cash position 1 | 6.39 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 2.803 x | 16.01 x | 2.459 x | 1.647 x | -44.51 x |
| Free Cash Flow 1 | 48.2 | 74 | -41.8 | 20.6 | 44.8 | -11.5 |
| ROE (net income / shareholders' equity) | -4.45% | -42% | -0.36% | 1.6% | 6.55% | -8.27% |
| ROA (Net income/ Total Assets) | -0.07% | 1.27% | -1.16% | 2.57% | 2.04% | -2.02% |
| Assets 1 | 3,109 | -8,698 | -234 | -44.29 | 397.9 | 576.9 |
| Book Value Per Share 2 | 2.090 | 1.210 | 1.230 | 1.220 | 1.420 | 1.450 |
| Cash Flow per Share 2 | 0.1300 | 0.2100 | 0.3100 | 0.3100 | 0.5300 | 0.4400 |
| Capex 1 | 37.5 | 12.1 | 13.8 | 3.74 | 16.3 | 16.4 |
| Capex / Sales | 12.38% | 3.04% | 4.23% | 1.07% | 4.38% | 5.66% |
| Announcement Date | 3/28/19 | 3/30/21 | 3/31/21 | 3/30/22 | 3/31/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +17.50% | 17.38M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- 8247 Stock
- Financials Biosino Bio-Technology and Science Incorporation
